Meningococcal disease

Meningococcal disease is an infectious condition caused by Neisseria meningitidis, also known as meningococcus, which is a Gram-negative diplococcus bacterium. The disease encompasses several clinical syndromes, most notably meningococcal meningitis and meningococcal septicemia (meningococcemia), either individually or in combination. The infection is classified as invasive meningococcal disease (IMD) when it presents in its more severe form, involving sepsis and meningitis. The etiologic agent, Neisseria meningitidis, is a human-specific pathogen that can colonize the nasopharynx of healthy carriers without producing disease in the majority of cases.

Meningococcal disease presents along a spectrum from subtle initial symptoms that mimic other bacterial infections to fulminant, life-threatening illness. The two primary clinical manifestations are meningitis, characterized by inflammation of the meninges causing fever, neck stiffness, and altered mental status—though the classic triad is present in fewer than half of cases—and meningococcemia, a bloodstream infection accounting for approximately 20% of cases that can progress to septic shock, disseminated intravascular coagulation, and the characteristic petechial rash. Even with appropriate antibiotic therapy, approximately one in ten patients with meningococcal meningitis die, and a similar proportion of survivors experience lasting sequelae including limb loss, hearing impairment, or permanent neurological damage. Atypical presentations may include septic arthritis, pneumonia, pericarditis, or gastrointestinal symptoms such as nausea, vomiting, and abdominal pain.

Meningococcal disease occurs worldwide, affecting both developed and developing countries as a major cause of illness, death, and disability. The global incidence ranges from 0.0 to 10.2 cases per 100,000 population, though this figure varies considerably by region, age group, and circulating serotypes. Serotype B accounts for the majority of new cases globally, though the distribution of serogroups differs across geographic areas. The introduction of meningococcal conjugate vaccines has substantially reduced disease incidence in countries with established immunization programs, demonstrating the impact of vaccination on population-level disease burden. The bacterium commonly colonizes the nasopharynx of healthy individuals, with invasive disease occurring in only a small percentage of those colonized.

Meningococcal disease is transmitted through direct contact with respiratory secretions or saliva from infected individuals, including through close contact that involves sharing respiratory droplets. The bacteria can spread via inhalation of respiratory air droplets expelled during coughing, sneezing, or close conversation. Transmission requires relatively close contact with an infected person or carrier, as the organism does not survive well outside the human host. Asymptomatic nasopharyngeal carriage serves as the primary reservoir for transmission to susceptible individuals.

Source-backed detail on specific high-risk groups is not yet available in the provided snippets, though the disease's epidemiology indicates that children, adolescents, and individuals in crowded living conditions face elevated exposure risk based on transmission dynamics and observed incidence patterns.

Prevention of meningococcal disease relies primarily on vaccination, which has proven highly effective in reducing disease incidence in populations with comprehensive immunization programs. Several vaccine types are available targeting different serogroups of Neisseria meningitidis, with serogroup B vaccines addressing the most common circulating strain worldwide. Public health measures in outbreak settings may include chemoprophylaxis for close contacts of confirmed cases to eliminate nasopharyngeal carriage and prevent secondary cases. Vaccination is particularly important for individuals at increased risk, including adolescents, college students living in dormitories, and those with certain medical conditions that predispose to invasive disease.

Meningococcal disease surveillance serves multiple public health functions, including monitoring disease incidence, detecting outbreaks, tracking circulating serogroups, and evaluating the impact of vaccination programs. The relatively low global incidence (0-10.2 per 100,000) combined with the disease's rapid progression and high mortality means that surveillance systems must be sensitive enough to capture all suspected cases while maintaining the capacity for rapid laboratory confirmation. Serogroup distribution data are essential for vaccine program planning and outbreak response. Given that the disease can progress from symptom onset to death or severe disability within hours, surveillance data must support timely public health action, including identification of close contacts for prophylaxis and detection of potential outbreak clusters requiring coordinated response.

1. 1 Wikidata. meningococcal disease.
2. 2 Wikipedia. Meningococcal disease - Wikipedia.

ICD-10

ICD-11

Total cases

15K

Total deaths

213

Peak month

2010-03

Coverage

4 reporting countries · 2000-01-01 → 2026-05-09